Gynecologic Oncology

Panelists discuss how tisotumab vedotin represents a practice-changing but modest improvement in cervical cancer treatment, with only 1.5-month progression-free survival benefit and notable ocular toxicities, while emphasizing the need for better patient access to required ophthalmologic monitoring.

Panelists discuss how cervical cancer treatment guidelines have rapidly evolved to incorporate pembrolizumab across multiple settings, from locally advanced disease with positive nodes to metastatic disease, while emphasizing the importance of comprehensive biomarker testing including PD-L1 and HER2 status for optimal treatment selection.

Selinexor improved PFS, TFST, TSST, and PFS2 in TP53 wild-type advanced/recurrent endometrial cancer.

Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.

Pembrolizumab plus chemoradiation with maintenance pembrolizumab was safe and effective in unresectable vulvar cancer.

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

Cadonilimab plus chemotherapy with or without bevacizumab has received NMPA approval for first-line recurrent or metastatic cervical cancer.

An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

Linda R. Duska, MD, MPH, on incorporating immunotherapy into definitive therapy for high-risk, locally advanced cervical cancer.

Pembrolizumab plus CCRT showcases sustained survival benefits in high-risk locally advanced cervical cancer.

Experts from the gynecologic oncology space vote on their most anticipated abstracts on OncLive’s social media.

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Taliya Lantsman, MD, discusses future research directions for assessing dostarlimab/chemotherapy in endometrial cancer in the real-world setting.

Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.

Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the safety of letrozole, abemaciclib, and metformin in ER-positive, recurrent endometrial cancer.

Ramez N. Eskander, MD, discusses the limitations of biomarker analyses for guiding treatment decisions in pMMR endometrial cancer.

The FDA granted fast track designation to ADRX-0706 for locally advanced or metastatic squamous cell cervical cancer.

Matthew Wagar, MD, discusses the addition of T-DXd to the HER2-positive endometrial cancer treatment paradigm.

Adavosertib monotherapy demonstrated signs of antitumor activity in uterine serous carcinoma; however, the phase 2 starting dose was not well tolerated.

Shannon Westin, MD, MPH, FACOG, contextualizes data from an exploratory biomarker analysis of the phase 3 DUO-E trial in pMMR recurrent endometrial cancer.

Dana M. Chase, MD, discusses how patient preferences can inform treatment planning in gynecologic oncology.

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Núria Agustí, MD, discusses patient eligibility in a cohort study assessing adjuvant chemoradiotherapy vs radiotherapy alone in patients with cervical cancer.

Dostarlimab/chemotherapy was granted an expanded approval by Health Canada to treat patients with primary advanced or first recurrent endometrial cancer.